BioPharm Systems, a leading global IT consulting and managed services provider (MSP) specializing in Oracle's clinical trial, data, safety, and pharmacovigilance management systems, today announced that Sunovion Pharmaceuticals Inc. (Sunovion) has selected ASCEND for their clinical trial management system (CTMS). ASCEND is a pre-configured and enhanced version of Siebel Clinical, Oracle's CTMS. The system is configured to meet most organizations' CTMS requirements out-of-the-box, providing smaller organizations with what they need to get started and larger organizations with a robust base for their more complex needs.
For Sunovion, BioPharm Systems will implement ASCEND with minor custom configurations and integrate the system with the company's two preferred contract research organizations' (CROs') CTMS solutions. In addition, Sunovion has elected to host ASCEND in the cloud in BioPharm Systems' state-of-the-art data center.
"We are honored to have Sunovion as one of our newest hosted ASCEND clients," said Param Singh, vice president of clinical trial management solutions, BioPharm Systems. "Together, we have designed an implementation approach that involves rolling releases, which will allow Sunovion to finalize their process documentation, roll out training, and begin using their production system prior to all of the work streams being completed. This is cutting-edge and we are excited to get started."
Despite the complex nature of the project, the final work stream is scheduled to go live this year. Sunovion is planning more integrations with ASCEND over the next three years, including their clinical inventory management system (CIMS), electronic document management system (EDMS), Oracle Health Sciences Clinical Development Analytics (CDA) solution, as well as additional CROs.
BioPharm Systems is a Gold level member of Oracle PartnerNetwork (OPN) and an Oracle Accelerate solution provider. The company has achieved Specializations in Oracle Argus Safety Suite, Oracle Life Sciences Data Hub, and Oracle Accelerate for Midsize Companies.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.